Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2017
At a glance
- Drugs Capecitabine (Primary) ; Everolimus (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 27 Sep 2016 Status changed from recruiting to active, no longer recruiting.